|Mr. Christian S. Schade||Pres, CEO & Chairman||656.51k||N/A||1961|
|Mr. Scott M. Coiante||Sr. VP, Company Sec. & CFO||320.79k||N/A||1967|
|Dr. Eyal C. Attar M.D.||Sr. VP & Chief Medical Officer||523.39k||N/A||1971|
|Dr. Lars B. Abrahmsen||Sr. VP & Chief Scientific Officer||N/A||N/A||1957|
|Dr. Gregory A. Korbel Ph.D.||Sr. VP & Chief Bus. Officer||N/A||N/A||1976|
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 8.